Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer Journal Article
| Authors: | Zelefsky, M. J.; Chan, H.; Hunt, M.; Yamada, Y.; Shippy, A. M.; Amols, H. |
| Article Title: | Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer |
| Abstract: | Purpose: We report on the long-term results and late toxicity outcomes of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. Materials and Methods: Between 1996 and 2000 a total of 561 patients with clinically localized prostate cancer were treated with intensity modulated radiation therapy. All patients were treated to a dose of 81 Gy prescribed to the planning target volume. Prostate specific antigen relapse was defined according to the American Society for Therapeutic Radiology and Oncology consensus and Houston definitions (absolute nadir plus 2 ng/ml dated at the call). Median followup was 7 years (range 5 to 9). Results: The 8-year actuarial PSA relapse-free survival rates for patients in favorable, intermediate and unfavorable risk groups according to the American Society for Therapeutic Radiology and Oncology definition were 85%, 76% and 72%, respectively (p <0.025). The 8-year actuarial prostate specific antigen relapse-free survival rates for patients in favorable, intermediate and unfavorable risk groups according to the Houston definition were 89%, 78% and 67%, respectively (p = 0.0004). The 8-year actuarial likelihood of grade 2 rectal bleeding was 1.6%. Three patients (0.1%) experienced grade 3 rectal toxicity requiring either 1 or more transfusions or a laser cauterization procedure. No grade 4 rectal complications have been observed. The 8-year likelihood of late grade 2 and 3 (urethral strictures) urinary toxicities were 9% and 3%, respectively. Among patients who were potent before intensity modulated radiation therapy, erectile dysfunction developed in 49%. The cause specific survival outcomes for favorable, intermediate and unfavorable risk cases were 100%, 96% and 84%, respectively. Conclusions: These long-term results confirm our previous observations regarding the safety of high dose intensity modulated radiation therapy for clinically localized prostate cancer. Despite the application of high radiation doses, the incidence of rectal bleeding at 8 years was less than 2%. Despite the increased conformality of the dose distribution associated with intensity modulated radiation therapy, excellent long-term tumor control outcomes were achieved. © 2006 American Urological Association. |
| Keywords: | adult; treatment outcome; aged; aged, 80 and over; disease-free survival; middle aged; major clinical study; intensity modulated radiation therapy; cancer risk; radiation dose; follow up; follow-up studies; neoplasm staging; prostate specific antigen; radiotherapy; radiation injury; prostate cancer; prostate-specific antigen; prostatic neoplasms; radiotherapy, intensity-modulated; medical society; catheterization; cancer relapse; toxicity; time series analysis; urinary tract; rectum; rectum hemorrhage; radiation tolerance; urethra stricture; intensity-modulated |
| Journal Title: | Journal of Urology |
| Volume: | 176 |
| Issue: | 4 |
| ISSN: | 0022-5347 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2006-10-01 |
| Start Page: | 1415 |
| End Page: | 1419 |
| Language: | English |
| DOI: | 10.1016/j.juro.2006.06.002 |
| PUBMED: | 16952647 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 182" - "Export Date: 4 June 2012" - "CODEN: JOURA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work